<DOC>
	<DOCNO>NCT01345721</DOCNO>
	<brief_summary>The primary purpose study evaluate persistence bactericidal antibodies child approximately 22 45 month age previously enrol V59P22 study receive Novartis MenACWY Conjugate Vaccine Meningococcal C Conjugate Vaccine . This measured percentage subject human Serum Bactericidal Assay ( hSBA ) titer ≥ 1:8 directed Neisseria meningitidis serogroups A , C , W-135 , Y . In addition response one month post additional dose Novartis MenACWY measure percentage subject hSBA titer ≥ 1:8 GMTs .</brief_summary>
	<brief_title>Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine Meningococcal C Conjugate Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Children eligible enrol study whose parent provide write informed consent ; generally good health base clinical judgment investigator ; subject 2245 month age time enrollment V59P22E1 ; subject participate parent V59P22 study . Main exclusion criterion : Subjects serious , acute , chronic illness Subjects receive licensed vaccine within 28 day ( Exception : Influenza vaccine allow 14 day prior less 14 day study immunization ) prior enrolment study visit Subjects receive Meningococcal vaccine since study dose MenACWY Men C 12 month age V59P22 trial .</criteria>
	<gender>All</gender>
	<minimum_age>22 Months</minimum_age>
	<maximum_age>45 Months</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Meningococcal</keyword>
	<keyword>ACWY</keyword>
	<keyword>Conjugate Vaccine</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Toddlers</keyword>
	<keyword>Children</keyword>
	<keyword>Persistence</keyword>
	<keyword>Boost</keyword>
</DOC>